Starting on Wednesday, January 1st, Americans with Medicare will benefit from a $2,000 out-of-pocket spending cap on prescription drugs thanks to President Biden’s Inflation Reduction Act. That means that 19 million seniors and people with disabilities with Medicare are expected to save an average of $400 per year, in addition to savings from other provisions of the law. In August, the Biden-Harris Administration announced lower prescription prices for the first ten drugs that have been negotiated by Medicare. These new, lower prices take effect in 2026, and will cut the price of some of the most expensive and most commonly used drugs nearly 40 and 80%.
Today’s action builds on the progress the Biden-Harris Administration has already made lowering health care costs, including the Inflation Reduction Act’s $35 insulin cap, making recommended vaccines free for seniors, and requiring drug companies to pay a rebate when they raiseprescription prices faster than the rate of inflation. President Biden took on Big Pharma and won and because of this law, costs are going down for drugs that treat heart disease, cancer, diabetes, blood clots, and more
“I believe that health care should be a right – not a privilege – and throughout my presidency I have advanced that goal. This week, we take another step closer to an America where everyone can afford the quality health care they need, as Medicare’s new $2,000 cap on prescription drug costs from my Inflation Reduction Act goes fully into effect.
“Before I took office, people with Medicare who took expensive drugs could face a crushing burden, paying $10,000 a year or more in copays for the drugs they need to stay alive. When I took on Big Pharma and won, we changed that, capping seniors’ out-of-pocket spending on drugs they get at the pharmacy for the first time ever. Costs were capped at about $3,500 in 2024, and in just the first six months of the year, this policy saved people with Medicare $1 billion in cost-sharing. On January 1, 2025, the cap on drug costs fully phases in, and costs are now capped at $2,000 per year. As a result, 19 million people are expected to save an average of $400 each. That’s a game changer for the American people.
“My Inflation Reduction Act has changed Medicare for the better, and as a result Americans will have more money back in their pockets in the years to come.”
President Biden and Vice President Harris came into office determined to end the COVID-19 pandemic while making progress toward a world that is safe from biological threats. Today we are releasing the final annual global health security report of the Biden-Harris Administration, U.S. Government Support for Global Health Security – Protecting Lives and Safeguarding Economies, which highlights progress in global health security and identifies remaining challenges. This fact sheet was provided by the White House:
The Biden-Harris Administration has advanced a bold agenda to prevent the devastating toll of outbreaks and pandemics, including investing more than $3 billion in strengthening global health security (GHS) since 2020. These investments have helped to: prepare countries around the world to more effectively prevent, detect and respond to biological threats; build stronger and more effective regional and global institutions to support health emergency preparedness and response; and respond rapidly to numerous outbreaks – from Ebola to mpox – to limit the health and economic impacts on the American people, as well as people living around the world. U.S. leadership in global health security is built on decades of investments in global health and research and development, as well as strong partnerships with other countries, regional and multilateral institutions, civil society, and the private sector.
REDUCING THE RISK OF NEW THREATS EMERGING AND BUILDING COUNTRY CAPACITY TO RESPOND TO THREATS The most effective way to limit the impact of biological threats is to stop them at their source. The United States is working with countries and partners around the world to ensure they have the capacity to identify and stop emerging threats before they grow into regional or global threats. Central to these partnerships is the development of a shared plan based on gaps in each country’s capacity, as well as country ownership to sustain global health security capacities once U.S. Government support has ended. Highlights from the report include:
More than 100 countries are building stronger global health security capacities: Over the last four years, the Biden-Harris Administration expanded formal Global Health Security partnerships from 19 countries to more than 50 countries and one regional group. The United States has also leveraged financial resources and diplomatic channels to mobilize support for 50 additional countries to strengthen their health security capacities, for a total of more than 100 countries receiving support. For example, through U.S. support to the Pandemic Fund and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) COVID-19 Response Mechanism, over sixty countries received financing to strengthen core health security capacities. The United States is not the sole provider of these resources, as countries around the world contribute, including through co-financing by low and middle-income countries.
Measuring the impact of U.S. investments: The Biden-Harris Administration is focused on measurable results of these investments. Of the 25 formal GHS partner countries that have received U.S. support for at least two years, five have achieved the U.S. target of “demonstrated capacity” in at least five technical areas, and an additional five countries are close. We can also see the impact of investments when threats emerge. For example, the Democratic Republic of the Congo (DRC) – a U.S. government GHS partner since 2015 – has successfully contained five Ebola outbreaks since 2020, dramatically improving detection and response times. In 2022 the government of DRC detected an Ebola outbreak in 48 hours and contained the outbreak with only five lives lost to the disease.
Country ownership on global health security: Many United States GHS partner countries are leading their own responses to crises, with U.S. collaboration when needed. For example, the U.S. Government is partnering with Nigeria to build stronger capacity on zoonotic diseases, disease surveillance, and health emergency management, among other areas. In 2023, Nigeria experienced outbreaks of anthrax, a zoonotic disease that can cause severe illness in people and animals. Nigeria activated national response mechanisms to coordinate collaboration across the human and animal sectors and reduce the risk for further disease transmission. Nigeria also collaborated with Ghana to exchange strategies for anthrax prevention and control. These and other measures helped curtail the impact of anthrax in Nigeria.
Reducing the risk of biosafety and biosecurity incidents: Expanding biosurveillance capacity and the rapid evolution of technology are critical for health security, but can also elevate the risk of accidental and deliberate incidents. The Biden-Harris Administration has taken significant steps to minimize the chances of laboratory accidents; reduce the likelihood of deliberate use or accidental misuse; ensure effective biosafety and biosecurity practices and oversight; and promote responsible research and innovation. For example, the United States secured inclusion of biosafety and biosecurity as a critical component of the Pandemic Fund grants to support laboratory strengthening. One of the projects, the Caribbean Public Health Agency Train-the-Trainer Workshop on the Safe Transportation of Infectious Substances, resulted in certified trainers well-positioned to serve as national trainers and advisors in biosafety and safe transport protocols, ensuring safer practices across the region. The U.S. global health security bilateral partnerships also build capacity in biosafety and biosecurity: the GHS partner countries with at least two years of U.S. Government support demonstrated a net improvement in biosafety and biosecurity capacity from 2018 to 2023.
Modernizing biorisk management: The Administration released the 2024 United States Government Policy for Oversight of Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential, marking a major new step in modernizing biorisk management. This policy streamlines and expands oversight of research of concern across the entire U.S. Government – setting a new global standard for effective research oversight. The Administration also introduced a new framework for biotechnology safeguards on federally funded purchases of synthetic DNA and RNA. These safeguards, which include Know-Your-Customer screening, will reduce the likelihood of misuse of synthetic biology.
BUILDING MORE EFFECTIVE AND SUSTAINABLE GLOBAL HEALTH SECURITY GOVERNANCE AND FINANCING SYSTEMS Strong national systems within the United States and other countries are essential to global health security. However, each country, including the United States, operates within a regional or global system that can either facilitate or hamper quick and effective responses to health emergencies. The Biden-Harris Administration has invested in building stronger multilateral systems and partnerships to strengthen global health security. Multilateral Partnerships
Multilateral Negotiations: Through strong leadership and diplomatic outreach to World Health Organization (WHO) Member States, the United States helped secure an ambitious suite of amendments to the International Health Regulations (IHR) that will strengthen health emergency prevention, preparedness, and response. The United States is actively negotiating a pandemic agreement, with the goal of putting in place practical measures to prevent future pandemics, and strengthening the international community’s ability to respond rapidly and effectively in the event of a pandemic. The United States has also supported successful negotiations through the United Nations (UN) and UN agencies such as WHO on pandemic prevention, preparedness and response; antimicrobial resistance; biosafety and biosecurity; and biological weapons nonproliferation; among other areas.
Multi-country Partnerships: The Biden-Harris Administration has worked closely with our allies and partners to advance initiatives critical to improving health security. For example, the G20 has been instrumental in establishing and sustaining stronger links between health and finance ministries. The G7 has committed to support more than 100 countries to strengthen their global health security capacities, and has led progress in transforming pandemic preparedness and response financing. The U.S. Department of State launched the Foreign Ministry Channel for Health Security to foster greater diplomatic engagement among Foreign Ministries on global health security. The Quad, a diplomatic grouping between the United States, Australia, India, and Japan, delivered more than 400 million safe and effective COVID-19 vaccine doses to Indo-Pacific countries and almost 800 million doses globally; advanced health security priorities in the Indo-Pacific region; and recently launched the Quad Cancer Moonshot, which will deliver up to 40 million doses of the human papillomavirus vaccine and support other efforts to address cervical cancer to the Indo-Pacific. Since its inception in 2014, the United States has actively engaged in the Global Health Security Agenda (GHSA), a partnership of over 70 countries, more than 10 international organizations and coalitions, and more than 30 non-governmental organizations, including private sector and civil society partners, working together to accelerate implementation of the International Health Regulations.
Financing Limitations in the existing systems to finance pandemic prevention, preparedness, and response left countries and financial institutions ill prepared to effectively contain COVID-19, contributing to the health and financial crises that resulted in the deaths of over 1.2 million Americans and an estimated $14 trillion in economic losses to the U.S. economy. On day one, President Biden called on his Administration to transform the existing financing institutions and to cultivate new financing sources for global health security that are more effective and sustainable, and that are less dependent on U.S. government assistance.
Expanding Reliable Financing for Pandemic Prevention and Preparedness: The United States was instrumental in the creation of the Pandemic Fund in 2022, the only multilateral financing facility dedicated exclusively to pandemic preparedness financing for low- and middle- income countries. The Pandemic Fund made significant progress in its first two years, awarding grants totaling $885 million, which mobilized an additional $6 billion in investments, to support 75 countries and economies across six geographic regions. The Pandemic Fund also effectively pivoted to support countries to prepare for mpox outbreaks as part of the global response to the ongoing mpox public health emergency. The United States has supported the Pandemic Fund’s $2 billion replenishment goal by pledging up to $667 million by 2025, calling on other donors to step up their contributions and end the cycle of panic and neglect.
Strengthening Existing Financing Institutions to Support GHS: The United States is working to evolve Multilateral Development Banks to be better equipped to respond to the increasing frequency, scope, and complexity of global challenges, including pandemics. The Biden-Harris Administration strongly supported the establishment of the International Monetary Fund Resilience and Sustainability Trust and its goal of supporting low-income and vulnerable middle-income countries to access long-term, affordable financing to address longer-term challenges, such as health emergencies.
Improving Timely Access to Emergency Response Financing: During the COVID-19 pandemic, many countries and institutions lacked the liquidity to procure the medical countermeasures (MCM) needed to mount effective and timely responses. The U.S. Development Finance Corporation helped develop and lead a G7 Surge Financing Initiative, through which G7 development finance institutions (DFIs), the European Investment Bank, the International Finance Corporation, and global and regional health stakeholders are developing and deploying innovative financing tools to accelerate access to MCMs in health emergencies. The United States also supported the establishment of the Day Zero Financing Facility, a suite of tools that will enable Gavi, The Vaccine Alliance, to quickly meet demand for vaccines during a pandemic, including up to $2 billion in bridge financing loans. The United States also supports the roles of the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Fund, and other regional and multilateral organizations in the development of solutions to surge financing for MCMs during emergencies.
Increasing International Coordination and Cooperation in Health Security Financing: During health emergencies donors often surge rapid financial and technical support, with limited effective means for transparency and coordination, which can lead to inefficiencies, duplication of efforts, and gaps in support. The Biden-Harris Administration has taken action to enhance the impact of financing though increased coordination and cooperation including supporting the establishment of the G20 Finance-Health Task Force to strengthen coordination between Finance and Health Ministries; and contributed to improved international mpox response coordination.
EXPANDING ACCESS TO MEDICAL COUNTERMEASURES The Biden-Harris Administration has prioritized expanding access to quality medical countermeasures (MCMs) around the world, building on decades of global health and health security leadership by the United States. The United States has long led the world in innovation, research and development. The COVID-19 pandemic demonstrated the vital role of U.S. biotechnology and biomanufacturing in developing and producing the life-saving diagnostics, therapeutics, and vaccines needed to protect American lives and livelihoods, and national and economic security against future biological threats, whether naturally-occurring, accidental, or deliberate. The Biden-Harris Administration has strengthened sustainable global manufacturing and supply chain capacity; donated vaccines, diagnostic tests and treatments and support for their delivery; expanded pandemic response financing for MCMs; and strengthened legal and regulatory systems to ensure quality products and overcome barriers to rapid access.
Investments in Research and Development for Preparedness: While there will always be new or evolving biological threats, developing effective countermeasures for known threats is a critical piece of preparedness. For example, the U.S. government invested billions of dollars in mRNA technology in advance of the COVID-19 pandemic. These public investments translated into millions of lives saved in the United States and around the world, and were crucial to developing the mRNA vaccine technology that can be leveraged in a future pandemic, as well as potentially treating other diseases. The U.S. supports the goals of the mRNA Technology Transfer Programme, a capacity-building initiative in low- and middle-income countries to sustainably produce mRNA vaccines. Similarly, the United States Government invested more than $2 billion in the JYNNEOS vaccine as part of smallpox preparedness. These investments directly led to product licensure for both smallpox and mpox. On September 13, 2024, WHO announced pre-qualification of the JYNNEOS vaccine for global use, including in the Africa region in response to ongoing mpox outbreaks. The JYNNEOS vaccine that has now been used to protect Americans and people living around the world from mpox; it would not exist without the investment and technical expertise provided by the United States.
Investments in Biotechnology: The Biden-Harris Administration has prioritized transforming our biotechnology capabilities, including catalyzing advances in science, technology, and core capabilities and has advanced a whole-of-government approach to strengthening U.S. biotechnology and biomanufacturing, including for health security. The United States Government’s historic investments in science and technology, from basic science to piloting innovative financing mechanisms to real-time research during health emergencies, are transforming the tools and approaches we use to detect, contain and respond to health threats. These efforts support the ambitious international goal of developing vaccines, treatments and diagnostics within 100 days from the onset of a potential pandemic.
Support for theCoalition for Epidemic Preparedness Innovations (CEPI): CEPI is working to accelerate the development of life-saving vaccines against emerging disease threats, and to transform capability for rapid countermeasure development in response to future threats. Notable achievements include: the market authorization of the world’s first Chikungunya vaccine and technology transfer to regional producers for regional supply to LMICs; the advancement through clinical development of vaccine candidates against Lassa, Nipah, and coronaviruses, among others; and the launch of a new Disease X Vaccine Library with six viral families prioritized as high risk.
Expanding Access to Publicly-supported Medical Inventions: The U.S. supports broad access to medical inventions facilitated by public investments and science, including through: the NIH proposal to promote access to products that rely on NIH-owned inventions (“Promoting Equity Through Access Planning”); fair pricing guarantees in funding agreements between manufacturers and the Biomedical Advanced Research and Development Authority (BARDA); and appropriate provisions in a Pandemic Agreement for timely and equitable access to pandemic-related health products. During the COVID-19 pandemic, NIH licensed COVID-19 technologies arising from NIH intramural research to the Medicines Patent Pool (MPP) for access through WHO’s COVID-19 Technology Access Pool (C-TAP). Such contributions are an important step toward facilitating wider availability of lifesaving interventions around the world.
Respecting Countries’ Rights to Protect Public Health: The United States respects countries’ right to protect public health and to promote access to medicines for all. The United States respects and does not call out countries for exercising health rights and flexibilities enshrined in the World Trade Organization’s (WTO’s) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), including with respect to compulsory licenses, in a manner consistent with TRIPS obligations. Toward that end, the United States endorsed negotiations of a temporary waiver of WTO intellectual property rules to support access to COVID vaccines.
STOPPING BIOLOGICAL THREATS AT THEIR SOURCE In February 2021, just a few weeks into the Biden-Harris Administration and during the height of the COVID-19 pandemic, DRC and Guinea experienced two unrelated Ebola outbreaks. Since then, the United States Government has supported responses to numerous outbreaks, from Ebola disease and Marburg virus disease to mpox, avian influenza, Oropouche virus, as well as ongoing threats including dengue, cholera, measles, malaria and HIV. United States Government support to emergency response is closely linked with ongoing bilateral investments in preparedness, with the goal of each country developing the capacity and resources to lead and coordinate responses to threats as soon as they emerge. Examples of U.S. Government support to outbreak responses during the Biden-Harris Administration include:
COVID-19 Pandemic: Starting in 2021, the United States invested $16 billion in the global COVID-19 response. The Administration accelerated global access to COVID-19 vaccines, including sharing nearly 700 million COVID-19 vaccine doses with countries around the world, as well as diagnostics and therapeutics, supporting health workers, securing supply chains, and combatting mis- and disinformation on safe and effective COVID-19 vaccines. The United States was the world’s largest donor to the Access to COVID-19 Tools Accelerator (ACT-A) and provided global leadership to raise additional billions in critical funding through the U.S.-hosted and co-hosted Global COVID-19 Summits to save lives globally, end the pandemic, and build stronger health security.
Mpox Outbreaks: The world has faced two regional or global outbreaks of mpox during the Biden-Harris Administration. In 2022, the Biden-Harris Administration mounted a robust response to the spread of clade IIb mpox by making vaccines available to those at risk, making testing more convenient, and providing treatments to those who needed them both in the United States and worldwide. During the ongoing clade I mpox outbreak, the U.S. Government has committed over $500 million to support mpox preparedness and response activities in mpox-affected countries in Africa, and the U.S. Government has made more than one million mpox vaccine doses available for global use. The United States has delivered additional support through technical assistance and in-kind contributions to surveillance, case investigation, procurement of diagnostic kits, consumable reagents, other laboratory supplies, and personal protective equipment.
Marburg Virus Disease (MVD): After learning of the MVD outbreak in Rwanda in September 2024, the United States committed to making nearly $11 million available to address urgent health needs in Rwanda and surrounding countries, including for surveillance and contact tracing, infection prevention and control guidance, and exit screening. Within days of learning of the MVD outbreak, CDC deployed three senior scientists to Rwanda to support its response. Although there are currently no FDA-approved vaccines or drugs against MVD, the United States contributed thousands of investigational vaccine doses and a small number of investigational therapeutics doses, which arrived in Rwanda within a week of the U.S. Government learning of the outbreak. The United States has also contributed hundreds of MVD tests and units of personal protective equipment.
Enhanced U.S. Government Response Coordination: Building on work in previous Administrations, the Biden-Harris Administration has successfully shepherded the “Playbook for Biological Incident Response” and a “Biological Incident Notification and Assessment” protocol from concept stage to an established and well-exercised process for rapid communication and coordination when biological threats emerge. This playbook and the protocol serve to give U.S. federal agencies “off-the-shelf” tools to respond to biological threats from all sources – natural, accidental and deliberate – that avoid response delays that cost lives and resources.
While we have made progress since emerging from the acute phase of the COVID-19 pandemic, continued investment of financial, political, and technical resources is needed to ensure success in building stronger preparedness today, sustainability of those efforts, and resilience to future biological threats. Both at home and abroad, willingness to invest critical financial and political resources has waned as global health security competes with other priorities for attention and resources. Collective action across sectors and throughout the world is needed to ensure we do not cycle once more into neglect, rather that we sustain and build on the significant progress made. Success in these efforts will make Americans safer, protect our economy and reduce international reliance on U.S. resources and expertise during times of crisis.
The Biden-Harris Administration is proposing a new rule to significantly expand coverage of anti-obesity medications for Americans with Medicare and Medicaid. Tens of millions of Americans struggle with obesity. An estimated 42 percent of the U.S. population has obesity, which is now widely recognized as a chronic disease, with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.
Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%. But for too many Americans, these critical treatments are too expensive and therefore out of reach. Without insurance coverage, these drugs can cost someone as much as $1,000 a month.
Currently, Medicare and Medicaid cover the use of AOM’s for certain conditions, like diabetes. This proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees. Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation.
Since taking office, the President has built on, strengthened, and protected Medicare, Medicaid, and the Affordable Care Act, by signing laws such as the American Rescue Plan Act and the Inflation Reduction Act to lower prescription drug costs and health insurance premiums. The President is proud of the fact that the Inflation Reduction Act allows Medicare to negotiate down the price of drugs, a tool that will help Medicare lower the cost of some of the most expensive medications in the program. That power to negotiate drug prices is critical because Americans pay two to three times more than people in other countries for their prescription drugs. An analysis from the Department of Health and Human Services (HHS) finds international prices for anti-obesity medications are much lower than U.S. list prices and generally lower than U.S. net prices for these same medications. It’s unacceptable that Americans – especially those without insurance coverage for these drugs — are forced to pay so much more for life-saving medications. The proposed rule would be implemented at the same time as a comprehensive agenda to lower the costs of drugs, including the drug price negotiation program and increased market competition. We can lower drug prices and improve health outcomes for Americans.
Thanks to the President’s efforts, seniors are already seeing lower prescription drug costs with insulin capped at $35, free vaccines, and out-of-pocket costs for prescription drugs capped at $2,000 starting in 2025. Already this year, nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. Furthermore, HHS has reached agreement with drug manufacturers for the first ten negotiated drugs, with new prices that are reduced between 38 to 79 percent starting in 2026.
The President’s new actions are all in addition to an already impressive track record on fighting for the health care of Americans across the nation. The Biden-Harris Administration’s National Strategy on Hunger, Nutrition, and Health focused on ending hunger and reducing diet-related diseases such as obesity. One of the Strategy’s pillars is integrating nutrition and health, which recognizes the opportunities within Medicare and Medicaid to support beneficiaries’ access to nutritious foods, obesity counseling, and other nutrition-related services. Obesity is a multi-faceted disease and we need to work on all levels from prevention to treatment to address this persistent challenge.
As the Biden-Harris administration institutes new actions to protect women’s access to contraceptives and researchers have just published findings on risk factors for stroke that women – who suffer 57 percent of strokes – face, the administration just announced $110 million in awards from ARPA-H’s “Sprint for Women’s Health” to accelerate new discoveries and innovation. The President and First Lady recognized that medical research largely ignored women, focused almost entirely on men, and established the White House Initiative on Women’s Health Research.
Meanwhile, three states – Missouri, Idaho and Kansas (despite recently approving abortion rights – have revived the lawsuit that the Supreme Court rejected last year, to curb access to abortion medication. Indeed the fact that pregnancy is one of the factors in women’s increased risk of stroke demonstrates why increasing access to contraception and abortion medication is vital, along with the statistics which show spikes in maternal and infant mortality in states that ban abortion and have criminalized pregnancy. The stakes and the contrast in this election – by pro-women’s rights candidate Kamala Harris vs. anti-women’s freedom candidate Donald Trump, could not be more clear. Here is a fact sheet provided by the White House on the latest women’s health initiative. – Karen Rubin/[email protected], news-photos-features.com
President Biden and First Lady Jill Biden created the White House Initiative on Women’s Health Research to fundamentally change how our nation approaches and funds women’s health research. Despite making up more than half the population, women have historically been understudied and underrepresented in health research. Since its launch in November 2023, the Initiative has made significant investments to close gaps in research on women’s health—from menopause-related conditions to endometriosis to auto-immune conditions to cardiovascular disease—so that we can improve prevention, diagnosis, and treatment of diseases and conditions that affect women uniquely, disproportionately, and differently.
Today in Las Vegas, Nevada, the First Lady will announce $110 million in awards from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate transformative research and development in women’s health. President Biden established ARPA-H, a new research and development funding agency, with bipartisan Congressional support to generate high-impact biomedical and health breakthroughs. In February 2024, the First Lady launched ARPA-H’s Sprint for Women’s Health, the first major deliverable of the White House Initiative on Women’s Health Research. Over the last 10 months, ARPA-H received an unprecedented response to this call for solutions for women’s health, with over 1,700 submissions across 45 states and D.C. as well as 34 countries.
In less than a year, the White House Initiative on Women’s Health Research has galvanized nearly a billion dollars in funding for women’s health research, including the First Lady’s recent announcement of $500 million from the U.S. Department of Defense and $200 million from the National Institutes of Health. Additionally, in his State of the Union address, President Biden called on Congress to make a bold, transformative investment of $12 billion in new funding for women’s health research. President Biden also signed a first-of-its-kind Executive Order on Advancing Women’s Health Research and Innovation, directing the most comprehensive set of executive actions ever taken to expand and improve research on women’s health. Through the Initiative, federal agencies have committed to taking over 100 actions to prioritize investments in women’s health research and integrate women’s health across the federal research portfolio.
Accelerating Progress in Women’s Health Research
Today’s ARPA-H awardees will spur innovation and advance high-impact, novel approaches to diseases and conditions that affect women uniquely, disproportionately, and differently. Today’s awardees are working across a range of women’s health issues—from pursuing new ways to prevent, detect, and treat cardiovascular conditions, ovarian cancer, endometriosis, neurological diseases, and pain in women to developing next-generation approaches to menopause, migraines, obstetrics, and gynecological care.
One-quarter of today’s awardees are pursuing “launchpad” projects, meaning those projects have the potential for commercialization within two years. The remaining awardees are pursuing “spark” projects that are in the early stage of research. ARPA-H’s support for these projects will help ensure that women and their health care providers can soon benefit from the research investments being made today.
The $110 million in ARPA-H awards announced today across 23 teams fund bold and transformative women’s health solutions, including:
Aspira Women’s Health Inc. of Shelton, Connecticut will receive $10 million to create a first-of-its-kind definitive, non-invasive blood test to diagnose endometriosis. Endometriosis is a debilitating condition that affects about 1 in 10 women and often takes years and surgery to be diagnosed. Aspira Women’s Health Inc. aims to reduce the time it takes to diagnose endometriosis from years to days while helping health care providers identify the most appropriate treatment option for each woman’s needs.
Beth Israel Deaconess Medical Center, Inc. of Boston, Massachusetts will receive $9.1 million to improve our ability to assess brain disorders in women through a novel non-invasive MRI imaging biomarker. Even though conditions such as Alzheimer’s disease, dementia, and multiple sclerosis disproportionately affect women, there are significant gaps in our knowledge about how to prevent, detect, and treat these conditions in women. By developing a novel and non-invasive MRI technology to measure a specific brain protein, Beth Israel Deaconess Medical Center, Inc. will advance our understanding of, and improve treatments for, brain disorders in women.
Children’s Research Institute of Washington, DC—through its research arm on families—will receive $8.1 million to develop a novel way to assess chronic pain in women. Women experience pain differently than men which can lead health care providers to underestimate and undertreat this pain, resulting in prolonged suffering, delayed diagnosis and treatment, and a reluctance to seek medical care. Despite this need, there is currently no objective, quantitative indicator of chronic pain in women. Children’s Research Institute aims to fill this gap by studying how a woman’s eyes react to external stimulation, which is directly related to how she perceives pain.
Gravidas Diagnostics, Inc. of Los Angeles, California will receive $3 million to create a first-of-its-kind at-home test to revolutionize our ability to detect early preeclampsia, a leading cause of maternal mortality and morbidity. By making it easier to identify preeclampsia quickly, Gravidas Diagnostics Inc.’s new low-cost fingerstick test would help women and their doctors get the information they need sooner to reduce pregnancy-related complications and improve maternal and child health.
The University of Iowa will receive $10 million to revolutionize the treatment for late-stage and metastatic ovarian cancer by using personalized nanoparticles to boost a woman’s immune system. More than half of women with ovarian cancer are diagnosed only after the cancer has metastasized, making it harder to treat and reducing survival rates. Leveraging nanotechnology, the University of Iowa will engineer personalized nanoparticles to use a woman’s own immune system to attack multiple cancers and help more women get the treatment they need to live longer.
Additional information and a full list of awardees is available here.
Long Island will soon become the epicenter for some of the most important medical breakthroughs in the world, with the opening of New York BioGenesis Park, a Cell and Gene Therapy Innovation Hub.
New York Governor Kathy Hochul unveiled the plans for the state-of-the-art facility, to be developed by The Albanese Organization, Inc., to catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York’s diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.
“With this groundbreaking hub, New York has the opportunity to stake its claim as the epicenter of cell and gene therapy innovation,”Governor Hochul said. “We’re not just advancing medical science; we’re creating a powerhouse that will drive our economy, generate thousands of high-skilled jobs, and bring hope to millions facing life-threatening diseases. This investment reaffirms our commitment to leading the future of healthcare and ensuring that the next medical breakthrough happens right here in New York.”
Cell and gene therapies are revolutionary treatments that modify a patient’s cells or genes to combat diseases at their source. Offering hope for previously incurable conditions—including cancers, genetic disorders, and autoimmune diseases—these approaches target illnesses at the cellular and genetic levels. They have the potential to provide more effective, longer-lasting treatments with fewer side effects than traditional methods. Advancements in these therapies could revolutionize healthcare, paving the way for personalized medicine and new possibilities for patients who have exhausted other treatment options.
“For people in the business, the healthcare professions of treating those who have complex diseases, this is an extraordinary opportunity,” Governor Hochul said. “And, cell and gene therapy, CGT, is one of the fastest growing treatment tools in the toolkit we have to deal with many, many diseases, and it’s near unlimited potential when it comes to changing outcomes for people diagnosed with cancer and rare diseases.”
With CGT, she said, cells are grown outside the body, genes are modified to eradicate harmful mutations, and then they’re fine-tuned by specialists in a lab, introduced into the patient where they go directly to work attacking cancerous cells and replacing faulty genes.
“It’s extraordinary when you think about that. Extraordinary. And, doctors call these therapies, not just miraculous, but a true paradigm shift. And their application is absolutely limitless. And, we think about the diseases that we’re trying to tackle. Those that have affected our own family members.”
Diseases that are considered incurable today: Parkinson’s, ALS, Multiple Sclerosis, heart disease, cancer, could be prevented, diagnosed, treated and cured using these technologies.
New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration. The project would be developed in multiple phases, with Phase One comprising a 331,000-square-foot facility on Northwell Health’s campus in Lake Success, including the first Cell and Gene Therapy Tower and Contract Development and Manufacturing Organizations (CDMO) Tower. Phase One is already poised to advance, with conditional commitments from two anchor tenants; one would operate the CDMO, the other would operate the incubator.
A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD’s Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.
This initial phase is expected to create approximately 830 full time union construction jobs and a combined estimate of 700 jobs related to Cell and Gene Therapy development and provision of services and technologies required by Cell and Gene Therapy developers, such as Contract Development and Manufacturing Organizations, vector developers, and advanced diagnostic providers, as well as staff required for operation of the Center. Phase Two would further expand lab and office space, enhancing the park’s capabilities for Cell and Gene Therapy companies and service providers.
Governor Hochul said that she expected the zoning and environmental studies to be completed by 2026 and the first phase – a 7,000 sq. ft. facility of what will ultimately be 330,000 sq. ft. to support research, development, education, and commercialization – to open by 2029. In the meantime, researchers are already at work in existing labs.
“New York BioGenesis Park represents a transformative investment in Long Island’s future and New York State’s position as a global leader in biotechnology advancements,” Empire State Development Board Chairman Kevin Law said. “This project not only promises to create hundreds of high-skilled jobs but also establishes a world-class ecosystem for cell and gene therapy innovation. By leveraging Long Island’s exceptional talent pool and research institutions, we’re laying the foundation for breakthroughs that will save lives and drive economic growth for decades to come.”
The state, through its Empire State Development office, is providing $150 million of the $430 million development cost, which will support 830 construction jobs and 700 full-time jobs – “as close as it gets to a sure bet,” Hochul said because CGT that this global market is going to go from $8.5 billion a year to over $21 billion a year, and projected to be worth over $120 billion in a few years.
“We’ll be at the forefront of this movement with these investments today. So, I want to make sure that we know that Long Island, again, is at the forefront of this. This is a new, whole new market, a whole new opportunity for us and thousands of jobs being constructed here and beyond.”
Governor Hochul had designated Long Island as a hub for life sciences and technology innovation, climate and renewable energy. She noted that Long Island has the nation’s largest offshore wind facility that is commercial utility grade “and we’re just getting warmed up.” The state has designated Stony Brook University as one of two flagships.
All of this contributes to the sense of Long Island’s “exceptionalism, that there’s nothing holding us back because we have everything. We have the smartest people, the most incredible academic institutions. We have research.
“You think about what’s happening all over, every corner of this island. It is the place that people want to be who are inventing the future. And the future of healthcare is so much brighter now. The doctors, and researchers and the therapists who are coming here. And they’ll be building their lives here on Long Island. Now we need to build them some homes, but that’s another topic, okay? Let’s give them a place to live.
“And, we’re making progress there, and I want to continue to make this one of the most desirable places to live in all of New York, because it truly is. And having all these academic institutions and people coming here, young people coming here for an education, an opportunity to work in this innovative field, will then say, ‘I don’t have to go back to the home state I came from. I can stay right here and build a beautiful life’.”
“But what this technology gives, more than anything else, is hope to people whose lives are changed overnight with a diagnosis.
“You don’t have to be relegated to the same outcome you would have, but for these investments, but for this technology, but for this innovation. And, so, I do believe that New York state will become America’s premier CGT innovator, and I’m counting on it happening right here.”
“My friends, all of you who are involved with this, I honor you. This is one of the most impactful things we’ll do. In our time in these positions in elective office, and to all those in the medical profession who truly believe in this and the ones who are coming up with innovations and taking more time off the clock to get these products to market, to get them into people and help save their lives.
“So, we can’t control everything, but an opportunity here today to free people from a life of pain, uncertainty, and even death — that’s why we’re here today. That moral obligation we have to leave this place better than we found it. After today, we can say we accomplished this. We are leaving this place better than we found it.
“Healing the sick, giving people hope who are hopeless. That’s as good as it gets, my friend. Thank you for being part of this extraordinary story. Thank you everyone who’s involved in this.”
New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state. New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York’s institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.
The New York BioGenesis Park and the Cell and Gene Therapy manufacturing expansion at Roswell Park would create a powerful, interconnected network that leverages complementary resources and capabilities at both ends of the state. By fostering a comprehensive ecosystem that spans from basic research to clinical application and commercialization, New York is positioning itself as the nation’s leading destination for Cell and Gene Therapy research, development, and manufacturing.
Northwell Health President and CEO Michael J. Dowling said, “We are committed to supporting New York State in establishing this innovative cell and gene therapy hub on Long Island. The facility will be a game changer for physician-scientists, researchers and innovative companies, some of which are already working together in the region to advance novel biomedical treatments in the fight against cancer and other devastating diseases, offering new hope for our diverse communities across the state.
“This is an investment in life-saving technology. We will be doing things never done before, expand on what we think we can do, It’s also about prevention, not just treatment, and recovery. This is an investment in collaboration and partnerships, working across all research areas, the best minds, researchers, intellectuals, to work together to create a new future,” Dowling said. “Imagine what could happen. This is a legacy event.”
The setting of the new campus is ideal – in close proximity to two other Northwell campuses and the largest ambulatory cancer center in the region.
The Albanese Organization, Inc., a Long Island-based developer with more than 70 years of experience in managing public-private partnerships, was selected following a Request for Proposals issued in December 2023 to lead the comprehensive process to design, finance, build, market, tenant, and operate the Long Island Cell and Gene Therapy Center. “This selection ensures that the project will be executed from conception to operation with an experienced development team, leveraging Albanese’s extensive expertise in developing large life science innovation campuses,” the state said.
“The Albanese Organization and our development team are honored and excited to be designated by Empire State Development to enter into this public private partnership that will realize the Governor’s vision to create a ‘Hub of the Future’ for Cell and Gene Therapy in Lake Success, Long Island. This transformative development will serve as a significant catalyst for advancing cell therapy research, development, clinical manufacturing, and commercialization across the State that will lead to increased access to transformative, life-saving treatments. The Hub will also further amplify and expand the economic engine that is the life sciences industry within New York State, and specifically Long Island.”
“The New York BioGenesis Park represents a transformative investment in Long Island’s future and solidifies our region’s position at the forefront of biotechnology innovation,” stated Long Island Regional Economic Development Commission Co-Chairs Linda Armyn and Dr. Kimberly R. Cline said.”This visionary project not only promises to create high-quality jobs and drive economic growth, but it also establishes Long Island as a global hub for cell and gene therapy research and development. By leveraging our region’s world-class academic institutions, skilled workforce, and entrepreneurial spirit, New York BioGenesis Park will catalyze breakthroughs that will save lives and shape the future of healthcare.”
State Assemblywoman Gina Sillitti, who helped win the funding, said, “New York State’s $150 million investment in a gene therapy research hub at Lake Success is a transformative step in developing Long Island’s biotechnology sector. I thank Governor Hochul for championing this initiative, which will create hundreds of jobs and further solidify Long Island’s place as a national leader in cutting-edge medical research and treatments.”
“New York is already a leader in the science of making ‘living cures’ from our own cells,” Roswell Park Comprehensive Cancer Center President and CEO Candace S. Johnson, PhD said. “With these historic investments in the Roswell Park GMP Engineering & Cell Manufacturing Facility and New York BioGenesis Park, Governor Kathy Hochul and Empire State Development are making sure our teams are supported by an innovation infrastructure powerful enough to transform their curiosity into cures”
New York Blood Center Enterprises President and CEO Christopher D. Hillyer, MD said,“The creation of the Long Island Center for Cell and Gene Therapy represents a critical investment in the future of medicine. New York Blood Center Enterprises and Comprehensive Cell Solutions are extremely proud to be part of the team that will position New York as a global leader in life sciences, particularly in cell and gene therapy, offering new hope to patients facing diseases once thought untreatable.”
Cold Spring Harbor Laboratory President and CEO Bruce Stillman, PhD said, “The New York State cell and gene therapy initiative on Long Island will be a most welcome addition to the region’s biomedical research enterprise, and Cold Spring Harbor Laboratory looks forward to partnering with the CGT initiative. We thank Governor Hochul and Empire State Development for pioneering this exciting research expansion.”
The Long Island Cell and Gene Therapy Innovation Hub stands to serve as a cornerstone of New York’s $620 million Life Science Initiative. Aimed at establishing the state as a national leader in the broader life sciences industry—including biotechnology, pharmaceuticals, and medical technology—the initiative allocates $320 million for strategic programs to attract new technologies, promote investment in emerging fields, and stimulate life science business growth and employment statewide. This multifaceted approach seeks to spur the development of a world-class research cluster, enhance the state’s ability to commercialize groundbreaking research, and drive economic growth.
By solidifying New York’s position in life sciences innovation, the initiative advances Cell and Gene Therapy development and strengthens the state’s global competitiveness. Read New York State’s Life Science Initiative Strategic Plan here.
Today, October 21, 2024, the Biden-Harris Administration proposed a rule to expand coverage of affordable contraception under the Affordable Care Act (Obamacare). Here is a memo from Jennifer Klein, Director of the White House Gender Policy Council which Biden established, and a fact sheet from the White House on the proposal:
Interested Parties Memo: Biden-Harris Administration Expands Coverage of Contraception Under the Affordable Care Act as Republican Elected Officials Continue Attacks on Reproductive Freedom From: Jennifer Klein, Director, White House Gender Policy Council
Under President Biden and Vice President Harris’s leadership, the Administration is taking bold action to expand coverage of contraception for the 52 million women of reproductive age with private health insurance, marking the most significant expansion of contraception benefits under the Affordable Care Act in more than a decade.
Today’s announcement builds on the Biden-Harris Administration’s strong record of defending access to reproductive health care and commitment to ensuring that women have the freedom to make deeply personal health care decisions, including if and when to start or grow their family.
Meanwhile, Republican elected officials continue to threaten women’s health, lives, and freedom through extreme abortion bans, some with no exceptions for rape or incest. Women are being denied essential medical care while doctors and nurses are threatened with jail time. Abortion, contraception, and IVF are under attack, while Republicans in Congress refuse to protect nationwide access to this vital reproductive health care. This extreme agenda is out-of-touch with the American people—which is why voters have overwhelmingly chosen to protect reproductive freedom in every state where abortion has been on the ballot.
President Biden and Vice President Harris stand with the vast majority of Americans in supporting a woman’s right to choose, and they will continue the fight against a national abortion ban and call on Congress to restore the protections of Roe v. Wade in federal law once and for all.
Read the Rest of the Interested Parties Memo Here Read President Biden’s Statement Here Read Vice President Harris’ Statement Here Read the Fact Sheet Here (and below)
FACT SHEET: Biden-Harris Administration Proposes Rule to Expand Coverage of Affordable Contraception Under the Affordable Care Act
Biden-Harris Administration Announces Proposal for Most Significant Expansion of Contraception Coverage Under the Affordable Care Act in More Than a Decade
President Biden and Vice President Harris have protected and built on the Affordable Care Act. Nearly 50 million people over the past decade have had coverage through the Affordable Care Act’s Marketplaces, and the law has protected more than 100 million people with preexisting medical conditions. Thanks to the Biden-Harris Administration, Affordable Care Act coverage is more affordable than ever with millions of families saving an average of $800 per year on Marketplace coverage.
The Affordable Care Act has also helped millions of women save billions of dollars on contraception—an essential component of reproductive health care that has only become more important since the Supreme Court overturned Roe v. Wade. As part of President Biden and Vice President Harris’ steadfast commitment to reproductive rights, the Biden-Harris Administration has further strengthened contraception access and affordability under the Affordable Care Act, through Medicare and Medicaid, through the Title X Family Planning Program, through federally qualified health centers, and for federal employees, Service members, veterans, and college students.
Today, the Biden-Harris Administration is proposing a rule that would significantly increase coverage of contraception without cost sharing for 52 million women of reproductive age with private health insurance. Building on the Affordable Care Act’s requirement that most private health plans must cover contraception without cost sharing, today’s proposed rule from the Departments of Health and Human Services (HHS), Labor, and the Treasury would:
Expand coverage of over-the-counter contraception without cost sharing. Under the proposed rule, for the first time, women would be able to obtain over-the-counter (OTC) contraception without a prescription at no additional cost. As a result, more women would be able to access and afford critical OTC medications such as emergency contraception and the first-ever daily oral contraceptive approved by the Food and Drug Administration (FDA) for use without a prescription that is now widely available across the country.
Make it easier to learn about coverage for OTC contraception. To help ensure that women understand this new benefit, most private health plans would be required to disclose that OTC contraception is covered without cost sharing and without a prescription—and take steps to help women learn more about their contraception coverage.
Strengthen coverage of prescribed contraception without cost sharing. The proposed rule would make it easier for most women with private health insurance to obtain contraception without cost sharing that is prescribed by their health care provider. Health plans would be required to cover every FDA-approved contraceptive drug or drug-led combination product without cost sharing unless the plan also covers a therapeutic equivalent without cost sharing, eliminating barriers that some women continue to face in accessing contraception prescribed by their provider.
This proposed rule, if finalized, would be the most significant expansion of contraception coverage under the Affordable Care Act since 2012, when contraception was first required to be covered. Also today, the Biden-Harris Administration is issuing new guidance to help ensure that patients can access other preventive services, such as cancer screenings, that must be covered without cost sharing under the Affordable Care Act.
The Biden-Harris Administration is issuing this proposed rule at a time when reproductive rights are under attack, and Republican elected officials remain committed to repealing the Affordable Care Act. Following the Supreme Court’s decision to overturn Roe v. Wade, dangerous and extreme abortion bans are putting women’s health and lives at risk and disrupting access to critical health care services, including contraception, as health care providers are forced to close in states across the country. At the same time, Republican elected officials in some states have made clear they want to ban or restrict birth control in addition to abortion, and Republicans in Congress have attacked contraception access nationwide by proposing to defund the Title X Family Planning Program. In contrast, President Biden and Vice President Harris believe that women in every state must have the freedom to make deeply personal health care decisions, including the right to decide if and when to start or grow their family.
Expand contraception coverage and affordability under the Affordable Care Act. The Departments of HHS, Labor, and the Treasury proposed a rule to provide a new pathway under the Affordable Care Act for women to access coverage of contraceptives when their private health coverage is exempt from covering this benefit due to a religious objection. These agencies also issued new guidance to support expanded coverage of a broader range of FDA-approved, cleared, or granted contraceptives at no additional cost under the Affordable Care Act, building on guidance issued after Roe v. Wade was overturned to clarify protections for contraceptive coverage under the Affordable Care Act. Further, HHS strengthened the standard for inclusion of family planning providers in Marketplace plan provider networks and provided nearly $9 million in grant funding to support state efforts to enhance and expand coverage of, and access to, reproductive and maternal health services, including contraception. And the Internal Revenue Service issued newguidance affirming that high-deductible health plans can cover OTC contraception as preventive care.
Bolster family planning services through Title X clinics. HHS continues to rebuild and grow the Title X Family Planning Program, which has played a critical role in ensuring access to a broad range of high-quality family planning and preventive health services for more than 50 years. During the prior administration, more than 1,000 service sites left the Title X Family Planning Program, leading to a significant decline in people served. The Biden-Harris Administration reversed the policy changes that led to those departures, strengthening the Title X Family Planning Program and helping ensure that the Program remains a critical part of the nation’s health safety net. In 2023, HHS provided about $287 million to nearly 4,000 Title X clinics across the country to provide free or low-cost voluntary, client-centered family planning and related preventive services for 2.8 million women and families—an 80 percent increase since 2020.
Support family planning coverage through the Medicaid and Medicare programs. The Centers for Medicare & Medicaid Services (CMS) issued new guidance to state Medicaid programs and Children’s Health Insurance Programs (CHIP) to help ensure that enrollees can access family planning services. The new guidance outlined existing state obligations under federal law, highlighted strategies to enhance access to contraception, affirmed confidentiality requirements for those seeking family planning services, and shared recommendations on ways to measure quality in delivering family planning services. To help ensure that women with Medicare coverage have access to more covered types of contraception without unnecessary barriers, CMS updated its Medicare Part D formulary clinical review process for plan year 2024 and 2025 to include additional contraceptive types, such as long-acting contraceptives, and is increasing public awareness of contraceptive coverage options under Medicare Part B. The Secretary of HHS also issued a letter to state Medicaid and CHIP programs as well as private health insurers and Medicare plans about their existing obligations to cover contraception for those they serve.
Increase contraception access through federal health centers. Federal health centers continue to be an important source of family planning services: in 2023, health centers provided nearly 3 million contraceptive services visits to patients, a 14 percent increase since 2020. To support health centers in providing high-quality family planning services, the Health Resources and Services Administration (HRSA) provided updated guidance on existing federal requirements for family planning and related services, which is a required primary health care service under federal law, as well as evidence-based recommendations and resources. HRSA also adopted new data measures for health centers that will help assess whether patients have been screened for contraception needs. Screening and data measures will help enhance the overall delivery of voluntary family planning and related services.
Support contraception access for federal employees and their families. The Office of Personnel Management strengthened access to contraception for federal workers, retirees, and family members by issuing guidance to insurers participating in the Federal Employee Health Benefits Program to clarify standards and support expanded coverage of a broader range of FDA-approved, cleared, or granted contraceptives at no additional cost. The Office of Personnel Management also required insurers that participate in the Federal Employee Health Benefits Program to take additional steps to educate enrollees about their contraception benefits and launched a public education campaign to highlight contraception benefits available to federal employees and their families.
Promote contraception access and affordability for Service members and their families and certain dependents of veterans. To improve access to contraception at military hospitals and clinics, the Department of Defense expanded walk-in contraceptive care services for active-duty Service members and other Military Health System beneficiaries and eliminated TRICARE copays for certain contraceptive services. And the Department of Veterans Affairs eliminated out-of-pocket costs for certain types of contraception through the Civilian Health and Medical Program of the Department of Veterans Affairs.
Support access to affordable contraception for college students. To help increase access to contraception for college students, President Biden directed the Secretary of Education to convene institutions of higher education to share best practices and ways to help students understand their options for accessing contraception. In 2023, Vice President Harris joined a Department of Education convening of representatives from 68 colleges and universities across 32 states to discuss promising strategies for protecting and expanding access to contraception for their students. This convening followed Vice President Harris’s multiple conversations about reproductive health access with students on college campuses across the country.
Enhance contraception access through technical assistance and public-private partnership. In June 2023, HHS announced a new five-year public-private partnership to expand access to contraception with Upstream, a national nonprofit organization that provides health centers with free patient-centered, evidence-based training and technical assistance to eliminate provider-level barriers to offering the full range of contraceptive options. To date, HHS has connected Upstream to more than 130 health care clinics, resulting in partnerships that will help Upstream accelerate their national expansion to reach 5 million women of reproductive age every year.
Promote research and data analysis on contraception access. To document the gaps and disparities in contraception access as well as the benefits of comprehensive coverage, HHS convened leading experts to discuss the state of research, data collection, and data analysis on contraception access and family planning services. These convenings helped identify research gaps, opportunities for collaboration, and ways to bolster research efforts for both Federal agencies and external partners.
In addition to strengthening access to affordable contraception, the Biden-Harris Administration continues to implement President Biden’s threeExecutiveOrders and a Presidential Memorandum directing federal agencies to protect access to reproductive health care issued since the Court overturned Roe v. Wade. To date, the Biden-Harris Administration has taken action to protect access to abortion, including FDA-approved medication abortion; defend access to emergency medical care; support the ability to travel for reproductive health care; safeguard the privacy of patients and health care providers; and ensure access to accurate information and legal resources.
The Vice President has led the White House’s efforts to partner with leaders on the frontlines of protecting access to abortion, highlighting the harm of abortion bans to women’s health at more than 100 events in more than 20 states since Roe v. Wade was overturned, and meeting with hundreds of state legislators, health care providers, and advocates. On what would have been the 51st anniversary of Roe v. Wade, the Vice President launched a nationwide Fight for Reproductive Freedoms tour to continue fighting back against extreme attacks throughout America.
President Biden and Vice President Harris will continue to call on Congress to restore the protections of Roe v. Wade in federal law to ensure that women in every state are able to make their own decisions about reproductive health care.
First Lady Jill Biden at the 2024 Clinton Global Initiative announced the Department of Defense’s new commitment to spend $500 million on vital women’s health research. With this new investment, the Department will fund research on conditions that affect women uniquely, disproportionately, or differently—such as ovarian cancer, rheumatoid arthritis, and musculoskeletal injuries. This commitment is consistent with President Biden’s Executive Order on Advancing Women’s Health Research and Innovation as well as the Department of Defense’s broader efforts to support the health of the women it serves and the medical readiness of the force.
The First Lady, joined by Chelsea Clinton, vice chair of the Clinton Foundation, and Dr. Valerie Montgomery Rice, president of Morehouse Medical School and an infertility specialist and researcher, also discussed the rapid progress being made by the White House Initiative on Women’s Health Research, which was launched less than a year ago with the goal of fundamentally changing how we fund and approach women’s health research, that included $100 million for transformative research and development in women’s health.
“Women are living longer, which means they are living longer with chronic pain,” Dr. Biden said to emphasize the need to determine why women are more likely to become afflicted by Alzheimer’s, MS, and auto immune diseases and no one knows why. Up until now, research on medications, therapies and treatments have only been developed with men as subjects. There has been virtually no study of ovarian health – arthritis, migraines – and why women getting these conditions.
President Biden was determined to do something about it, so allocated $100 million to ARPA-H – the mega-research agency of the government which Biden created to do health research in the same way ARPA researches and develops technology; then the National Institutes of Health allocated $200 million to study how menopause affects the brain, heart, and bone health. Now, the Department of Defense has allocated $500 million to study military women’s health, which will yield insights for all women.
Dr. Rice, a ground-breaking OB/GYN, said more study has to be done on how nutritional balance influences the cycle, how estrogen levels fluctuate throughout the cycle, and about lifestyle changes. “The only way we can understand how to introduce interventions is to include women in the studies early.” She added that social determinants must be considered in order to engender trust so women will volunteer to participate in clinical trials. “It starts with trial design.”
Monday’s CGI event followed the First Lady joining the top of the President’s Cabinet meeting last week, where she expressed gratitude to the agencies for their continued progress and momentum towards that goal. This was the first time the First Lady joined a Cabinet meeting and is a testament to how personally important this effort to advance women’s health research is for both the President and the First Lady.
Since launching the initiative last November, the First Lady has visited research centers and universities, and spoken with doctors and scientists across the country to understand the research questions we need to ask – and the answers they could find if we invest in women’s health.
“Since launching the White House Initiative on Women’s Health Research last November, the First Lady has put the spotlight on the urgent need to close the gap in how we fund and approach women’s health research,” FLOTUS Press Secretary Vanessa Valdivi stated.”The Biden-Harris Administration has quickly mobilized to make progress in less than year, and in the months ahead the First Lady will continue to push the work of this initiative forward, and build on the incredible momentum and enthusiasm we’ve seen across the public and private sectors.”
The White House Initiative on Women’s Health Research
The White House Initiative on Women’s Health Research is ensuring that research on women’s health is a priority and galvanizing new research on a wide range of topics. In his State of the Union address, President Biden called on Congress to make a bold, transformative investment of $12 billion in new funding for women’s health research. The President also signed an Executive Order on Advancing Women’s Health Research and Innovation that directed the most comprehensive set of executive actions ever taken to expand and improve research on women’s health.
The Initiative—led by the Office of the First Lady and the White House Gender Policy Council and Chaired by Dr. Carolyn M. Mazure —consists of executive departments and agencies across the federal government, such as the U.S. Departments of Health and Human Services, Defense, and Veterans Affairs, and White House offices, such as the Office of Management and Budget and the Office of Science and Technology Policy. Members of the White House Initiative on Women’s Health Research have already taken action to advance women’s health research, including:
The President’s Advanced Research Projects Agency for Health (ARPA-H) committed $100 million for transformative research and development in women’s health for its first-ever Sprint for Women’s Health. ARPA-H received an unprecedented response to its call for proposals, receiving submissions from a mix of scientific visionaries from across the globe and sectors.
The National Institutes of Health (NIH) launched a new agency-wide effort to invest $200 million for new, interdisciplinary women’s health research—a first step towards the transformative central Fund on Women’s Health that the President called on Congress to invest in. This cross-cutting effort will allow NIH to fund ambitious, multi-faceted research projects such as research on the impact of perimenopause and menopause on heart health, brain health and bone health.
The Department of Health and Human Services announced $12.5 million in new funding to address the unique mental health and substance use treatment needs of women. The new Women’s Behavioral Health Technical Assistance Center will help fill vital gaps in health care providers’ knowledge and ability to treat the mental health and substance use conditions of women across the nation.
The NIH launched a new challenge to accelerate the development of innovative technologies for the diagnosis of endometriosis, a debilitating condition that affects about 1 in 10 women and often takes years to be diagnosed. NIH will award $3 million in prizes to innovators who develop new technologies that make it easier and quicker to diagnose endometriosis.
The National Science Foundation (NSF) issued its first-ever call for novel and transformative science and engineering research focused entirely on women’s health. NSF has also convened experts in the fields of engineering, biomedical research, and advanced computing to identify ways to improve women’s health research—including how artificial intelligence and machine learning can revolutionize our understanding of menopause.
DoD and the Department of Veterans Affairs launched a new Joint Collaborative to Improve Women’s Health Research for Servicemembers and Veterans to further promote joint efforts to advance women’s health research and improve evidence-based care for women Servicemembers and veterans.
The First Lady joined Chelsea Clinton and Dr. Valerie Montgomery Rice at the Clinton Global Initiative to discuss women’s health research as part of the mainstage session, titled “Look Around,” where leaders from across the social impact spectrum highlighted the ways in which they break down barriers between peer institutions, cultivate partnerships and community, and align values and programs to create new, specific, and measurable ways to support one another.
As vice chair of the Clinton Foundation, Chelsea Clinton works alongside the Foundation’s leadership and partners to improve lives and inspire emerging leaders across the United States and around the world. This includes the Foundation’s early child initiative Too Small to Fail, which supports families with the resources they need to promote early brain and language development; and the Clinton Global Initiative University (CGI U), a global program that empowers student leaders to turn their ideas into action. A longtime public health advocate, Chelsea also serves as vice chair of the Clinton Health Access Initiative and uses her platform to increase awareness around issues such as vaccine hesitancy, childhood obesity, and health equity.
Dr. Valerie Montgomery Rice, president of Morehouse School of Medicine (MSM) and the first woman to lead the freestanding medical institution, is a renowned infertility specialist and researcher. She most recently served as dean and executive vice president of MSM, where she has served since 2011. Prior to joining MSM, Dr. Montgomery Rice held faculty positions and leadership roles at various health centers, including academic health centers. Most notably, she was the founding director of the Center for Women’s Health Research at Meharry Medical College—an HBCU in Nashville, Tennessee—one of the nation’s first research centers devoted to studying diseases that disproportionately impact women of color.
Dr. Montgomery Rice joined the President and First Lady for the Women’s Health Research Executive Order signing at the White House in March and participated in two White House Initiative on Women’s Health Research events with Dr. Biden in Atlanta, GA in February.
President Joe Biden Receives 2024 Clinton Global Citizen Award
Immediately after the panel discussion, president Joe Biden came onto the stage to surprise the CGI attendees, and perhaps be surprised himself by being awarded 2024 Clinton Global Citizen Award.
The award acknowledged Biden’s transformational presidency in taking the United States out of deadly COVID pandemic and double-digit unemployment, to the strongest recovery, the strongest economy, while transitioning the economy and society for economic, climate and civil justice, reestablishing the United States’ global leadership and standing up for democracy, peace and prosperity around the world, and standing up for country over personal interest.
As President Biden told the United Nations General Assembly just hours before, “I’ve made the preservation of democracy the central cause of my presidency. This summer, I faced a decision whether to seek a second term as president. It was a difficult decision. Being president has been the honor of my life. There is so much more I want to get done. But as much as I love the job, I love my country more. I decided, after 50 years of public service, it’s time for a new generation of leadership to take my nation forward.”
To the Clinton Global Initiative he said, “I am congenitally optimistic about this country. I really am… We’re good people. We really are. We just have to live up to what we expect of others,” in humbly accepting the award.
Previous Clinton Global Citizen Award winners have included First Lady of Ukraine Olena Zelenska (2023); Dolores Huerta (2022) for her advocacy of human rights of women, children and working class people worldwide; Nadia Mura (2016), a Yazidi woman who survived her capture and enslavement by ISIS and has become a voice for women and children trafficked in conflict; and Malala Yousafzai (2014) who survived an attack by the Taliban, targeted for going to school, and has gone on to be a strong advocate for girls’ education.
Two years ago, President Biden signed the Inflation Reduction Act, with Vice President Harris casting the tie-breaking vote in Congress. Not a single Republican voted for it and Trump/Vance and the Republicans vow to repeal it and replace it with Project 2025 laundry list of policies which will harm working and middle-class families. and undermine progress toward an equitable, sustainable economy. –Karen Rubin/news-photos-features.com
The Inflation Reduction Act is a key part of the Biden-Harris Administration’s Investing in America agenda, which has driven the fastest and most equitable recovery on record – creating good-paying jobs, expanding opportunity, and lowering costs in every corner of the country.
Already, the Inflation Reduction Act is transforming American lives by finally beating Big Pharma to negotiate lower prescription drug prices, making the largest investment in clean energy and climate action in history, creating hundreds of thousands good-paying jobs, lowering health care and energy costs, and making the tax code fairer.
Visit the White House Savings Explorer to see how Americans are saving money on their annual expenses because of the Inflation Reduction Act and other Biden-Harris Administration actions.
Statement from President Joe Biden on Inflation Reduction Act Anniversary
Two years ago, I signed the Inflation Reduction Act—the largest climate investment in history that is lowering energy costs and creating good-paying union jobs, while taking on Big Pharma to lower prescription drug costs—with Vice President Harris casting the tie-breaking vote. Already, this law is lowering health care costs for millions of families, strengthening energy security, and creating more than 330,000 clean energy jobs according to outside groups. It has also unleashed $265 billion in clean energy and manufacturing investments from the private sector in the last two years—part of the nearly $900 billion invested in America since we took office.
This historic legislation is fiscally responsible. It lowers the deficit over the long run by cutting wasteful spending on special interests and making big corporations and the wealthy pay more of their fair share. And just yesterday, my Administration announced lower prescription drug prices for the first ten drugs that have been negotiated by Medicare, which will cut the prices of drugs used to treat blood clots, heart disease, cancer, and more by nearly 40% to 80%, and save taxpayers $6 billion in the first year alone.
While Republicans in Congress try to repeal this law—which would increase prescription drug costs and take good-paying jobs away from their constituents, all to give massive tax cuts to big corporations—Vice President Harris and I will keep fighting to move our country forward by investing in America and giving families more breathing room.
Statement from President Joe Biden on Inflation Reduction Act Anniversary
Two years ago, I signed the Inflation Reduction Act—the largest climate investment in history that is lowering energy costs and creating good-paying union jobs, while taking on Big Pharma to lower prescription drug costs—with Vice President Harris casting the tie-breaking vote. Already, this law is lowering health care costs for millions of families, strengthening energy security, and creating more than 330,000 clean energy jobs according to outside groups. It has also unleashed $265 billion in clean energy and manufacturing investments from the private sector in the last two years—part of the nearly $900 billion invested in America since we took office.
This historic legislation is fiscally responsible. It lowers the deficit over the long run by cutting wasteful spending on special interests and making big corporations and the wealthy pay more of their fair share. And just yesterday, my Administration announced lower prescription drug prices for the first ten drugs that have been negotiated by Medicare, which will cut the prices of drugs used to treat blood clots, heart disease, cancer, and more by nearly 40% to 80%, and save taxpayers $6 billion in the first year alone.
While Republicans in Congress try to repeal this law—which would increase prescription drug costs and take good-paying jobs away from their constituents, all to give massive tax cuts to big corporations—Vice President Harris and I will keep fighting to move our country forward by investing in America and giving families more breathing room.
FACT SHEET: Two Years In, the Inflation Reduction Act is Lowering Costs for Millions of Americans, Tackling the Climate Crisis, and Creating Jobs
In the two years since the Inflation Reduction Act was signed into law:
Just yesterday, the President and Vice President announced that, for the first time in history, Medicare successfully negotiated lower prescription drug prices, which will save millions of seniors, people with disabilities, and other Medicare beneficiaries over $1.5 billion out-of-pocket in the first year.
Millions of Americans are saving an average of $800 per year on health insurance premiums because of cost savings from the American Rescue Plan that the Inflation Reduction Act extended, helping drive the nation’s uninsured rate to historic lows. 4 million seniors and other Medicare beneficiaries saved money on insulin because of the law’s cap at $35 for a month’s supply. 10.3 million Medicare enrollees received a free vaccine in 2023, saving them more than $400 million in out-of-pocket vaccine costs. The IRS successfully piloted Direct File in 12 states, saving 140,000 people an estimated $5.6 million in tax preparation fees by enabling them to file their taxes directly with the IRS online, for free. And, the IRS has recovered over $1 billion by cracking down on millionaire tax cheats since the law passed. Last year, 3.4 million Americans benefited from $8.4 billion in Inflation Reduction Act tax credits to lower the cost of clean energy and energy efficiency upgrades in their homes – significantly outpacing projections of the popularity of the tax credits in just the first year they were available. Since January 2024, more than 250,000 Americans have claimed the IRA’s electric vehicle tax credit, saving these buyers about $1.5 billion total. Nearly all of these buyers claimed the incentive at the point of sale. Since the beginning of the Biden-Harris Administration, companies have announced$900 billion in clean energy and manufacturing investments in the US, including over $265 billion in clean energy investments since the Inflation Reduction Act was signed into law. These investments are creating over 330,000 new jobs in the United States according to an outside group.
Economically distressed areas are poised to benefit the most from those investments. Over 99% of high-poverty counties in the United States are benefitting from an Investing in America project funded by the Inflation Reduction Act, Bipartisan Infrastructure Law, or CHIPS and Science Act. According to Treasury Department analysis, since the Inflation Reduction Act passed, 75% of private sector clean energy investments have flowed to counties with lower than median household incomes, and clean energy investment in energy communities has doubled. And, the Inflation Reduction Act is the largest investment in environmental justice in history.
Additionally, the Biden-Harris Administration has taken action to protect the critical investments that the Inflation Reduction Act is making in the domestic clean energy economy from unfair trade practices. In May, President Biden increased tariffs on $18 billion of Chinese imports to combat China’s artificially low-priced exports in strategic sectors such as electric vehicles, batteries, and solar. These actions protect American jobs, businesses, investments, and economic growth.
Lowering health care costs for millions of Americans
President Biden and Vice President Harris have made expanding access to high-quality, affordable health care and lowering prescription drug costs for American families a top priority. Thanks to the Inflation Reduction Act, health care is more accessible and more affordable than ever before. In just the last two years:
The law enhanced the Affordable Care Act’s financial assistance that is available to consumers to purchase health insurance. Millions of Americans are saving, on average, about $800 a year on their health insurance plans, with more than 80 percent of consumers able to find health insurance for $10 or less a month. As a result, a record-breaking 21 million people signed up for ACA coverage in 2024. That’s 9 million more than when the President and Vice President took office, and more underserved communities are enrolling in coverage, with 1.7 million Black Americans and 3.4 million Latinos enrolled, a 95% and 103% increase, respectively, since 2020.
The Inflation Reduction Act capped insulin costs at $35 for a month’s supply and making recommended adult vaccines free. Four million Medicare beneficiaries are now saving on their monthly insulin costs, and over 10 million beneficiaries received a free vaccine, saving more than $400 million in out-of-pocket cost. Drug companies that increase prices faster than inflation now have to pay a rebate to Medicare—which is translating into lower out of pocket costs for seniors. Next year, out of pocket drug costs will be capped at $2,000 per year for Medicare beneficiaries, which is expected to save nearly 19 million seniors an average of $400 per year.
The Inflation Reduction Act – for the first time ever – gives Medicare the power to negotiate lower prescription drug prices. Just this week, the Biden-Harris Administration announced new, lower prescription drug prices for all ten drugs selected for the first year of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program. The new, lower prices, which go into effect in 2026, will save American taxpayers $6 billion and will save seniors and people with disabilities $1.5 billion in out of pocket costs in 2026 alone. These new prices cut the list cost for drugs that treat heart disease, blood clots, diabetes, cancer, and more by nearly 40% to 80%.
Lowering energy costs with the largest climate investment in history
The Inflation Reduction Act is tackling the climate crisis by advancing clean power, cutting pollution from buildings, transportation, and industry and supporting climate-smart agriculture and forestry. The law is accelerating our progress toward President Biden and Vice President Harris’ goal of cutting U.S. climate pollution by 50 to 52 percent below 2005 levels in 2030.
Two years after the signing of the Inflation Reduction Act, the Biden-Harris Administration has made tremendous progress implementing the climate and clean energy provisions of this law quickly and effectively. Treasury guidance is now available for nearly all of the Inflation Reduction Act’s clean energy tax provisions. On the grant, loan, and rebate side of the law, nearly two thirds of Inflation Reduction Act funding has been awarded. As an example of the Administration’s rapid progress on implementation, today the Environmental Protection Agency announced that all $27 billion in awards through their Greenhouse Gas Reduction Fund are now obligated. $20 billion of these awards go toward a national clean energy financing network that will support tens of thousands of clean energy projects, reducing or avoiding millions of metric tons of carbon pollution annually over the next seven years. The other $7 billion in awards through the Solar for All program will save over $350 million each year on energy bills for over 900,000 low-income and disadvantaged households through residential solar.
In the two years since President Biden signed the Inflation Reduction Act into law:
Clean energy projects are creating more than 330,000 jobs in nearly every state in the country, according to outside groups.
Companies have announced $265 billion in new clean energy investments in nearly every state in the nation. According to Treasury Department analysis, many of these investments are happening in underserved communities—since the IRA passed, 75% of private sector clean energy investments made since the Inflation Reduction Act passed have occurred in counties with lower than median household incomes, and clean energy investment in energy communities has doubled. Last week, Treasury and IRS released new data showing that in 2023, more than 3.4 million American families saved $8.4 billion from IRA consumer tax credits on home energy technologies. These tax credits can save families up to 30% off heat pumps, insulation, rooftop solar, and other clean energy technologies. New York and Wisconsin have now launched home energy rebate programs, with more states expected to launch later this summer and fall. Already, 22 states have submitted their applications to DOE to receive their full rebate funding. These rebate programs help low- and middle-income families afford cost-saving electric appliances and energy efficiency improvements by providing rebates up to $14,000 per household. In total, the IRA rebates programs are expected to save consumers up to $1 billion annually in energy costs and support an estimated 50,000 U.S. jobs in residential construction, manufacturing, and other sectors.
Since January 2024, more than 250,000 Americans have claimed the Inflation Reduction Act’s EV tax credits—either $7,500 off a qualified new electric vehicle, or up to $4,000 off a qualified used electric vehicle. In total, these taxpayers have saved about $1.5 billion and nearly all buyers claimed the incentive at the point of sale.
Making the tax system fairer and making the wealthy pay their fair share
The Inflation Reduction Act fully pays for these investments, and reduces the deficit over the long run, by cutting wasteful spending on special interests and making big corporations and the wealthy pay more of their fair share. After 55 of the biggest corporations in America paid $0 in federal income tax on $40 billion in profits in 2020, the Inflation Reduction Act requires billion-dollar corporations to pay at least 15 percent in tax. It also requires corporations to pay a 1 percent excise tax on stock buybacks, encouraging businesses to invest in their growth and productivity instead of funneling tax-preferred profits to foreign shareholders. By making large corporations pay more of their fair share, the IRA will raise around $300 billion over a decade.
The Inflation Reduction Act also makes a historic investment in modernizing the IRS, providing funding to better taxpayer experience, reduce fraud, and upgrade critical technology infrastructure. Thanks to these investments, the IRS has already:
Improved services for millions of taxpayers. This spring, the IRS answered 3 million more phone calls than in 2022, cut phone wait times to three minutes from 28 minutes, served 200,000 more taxpayers in person, and saved taxpayers 1.4 million hours on hold last filing season. It also expanded online services, enabling 94% of taxpayers to submit forms digitally instead of via mail if they so choose.
Successfully piloted Direct File, allowing taxpayers to easily file their taxes online and for free, directly with the IRS for the first time. Over 140,000 Americans successfully filed their taxes through Direct File this year, claiming over $90 million in refunds and saving an estimated $5.6 million in tax preparation fees. Users said Direct File was easy and fast to use, with 90% rating their experience excellent or above average. Building on this success, the IRS has invited all 50 states and the District of Columbia to join Direct File starting in 2025.
Collected $1 billion from 1,500 millionaire tax cheats, launched enforcement action against 25,000 millionaires who have not filed a tax return since 2017, began audits on dozens of the largest corporations and partnerships, and cracked down on high-end tax evasion like deducting personal use of corporate jets as a business expense. At the same time, the IRS is adhering to Treasury Secretary Yellen’s commitment to not increase audit rates relative to current levels for small businesses and Americans making less than $400,000 a year.
Over the next decade, the Inflation Reduction Act’s investments will enable the IRS to further crack down on wealthy and corporate tax cheats and collect over $400 billion in additional revenue.
Going forward, the IRS is on track to implement additional improvements to taxpayer experience; provide additional in-person services in rural and underserved areas; redesign notices and forms to be less confusing; and expand online and mobile-friendly tools.
Investing in America to create jobs and expand opportunity
When President Biden thinks about climate change, he thinks about jobs. Two years into implementation of the Inflation Reduction Act, it’s easy to see why.
Across the nation, the Inflation Reduction Act is catalyzing a clean energy and manufacturing boom. Since President Biden took office, the Biden-Harris Administration’s Investing in America agenda has catalyzed nearly $900 billion in private sector investment commitments, including roughly $400 billion in clean energy across every state in the nation. That topline figure includes enough power generation to replace 40 Hoover Dams, the largest wind tower manufacturing facility in the world, the largest solar investment in US history.
Broader macroeconomic indicators also illustrate how, through tax credits and domestic content requirements within the law–we are successfully onshoring critical supply chains and encouraging a resurgence of domestic manufacturing. Real investment in manufacturing structures is at an all-time high—and has been for six quarters. Manufacturing’s contribution to GDP broke quarters for three consecutive quarters in 2023. And Americans have filed to open a record 300,000 new manufacturing businesses.
These investments are having real impacts on communities—particularly those that need it most. Public dollars are flowing disproportionately to disadvantaged and left behind communities: 99% of high-poverty counties have received funding from the infrastructure law, CHIPS Act, or Inflation Reduction Act, and non-metro communities have received nearly double the per capita funding of their urban counterparts. On the private sector side, analysis from the US Treasury tells a similar story. Since the IRA passed, 84% of announced clean investments have flowed to counties with college graduation rates below the national average, and the rate of investment in energy communities has more than doubled. Given these successes, it is no wonder that Republicans who voted against the bill are suddenly trying to take credit for it—and urging their leadership not to proceed with an unpopular repeal effort.
Statement from Vice President Kamala Harris on the Inflation Reduction Act Anniversary
Since day one of our Administration, President Joe Biden and I have made it a priority to strengthen the middle class by lowering costs, creating jobs, and advancing opportunity. That is why we fought to enact our Inflation Reduction Act, historic legislation that I was proud to cast the tie-breaking vote on in the Senate. In the two years since President Biden signed it into law, this landmark bill has already delivered for American families.
This transformational legislation is reducing the cost of health care for millions of people in communities across our nation – from capping the price of insulin at $35 a month for seniors to capping out-of-pocket drug costs at $2,000 a year for Americans on Medicare, which is expected to save nearly 19 million seniors an average of $400 per year. Additionally, Medicare is now able to negotiate lower prescription prices for millions of Americans while saving taxpayers billions by paying rates 40% to 80% lower for expensive medications used to treat conditions such as blood clots, heart disease, and cancer.
Our Inflation Reduction Act is also the single largest climate investment in American history. While taking on the climate crisis and lowering utility bills for families, it is helping us to rebuild American manufacturing and drive American innovation – creating good-paying union jobs, furthering economic opportunity, and contributing to the nearly $900 billion of private-sector investment since President Biden and I took office.
As we mark this two-year anniversary, President Biden and I recommit to doing everything in our power to ensure that families throughout our country have the freedom to thrive
New negotiated drug prices are expected to save millions of seniors and other Medicare beneficiaries $1.5 billion in out-of-pocket costs in the first year of the program alone. This fact sheet was provided by the White House:
For far too long, Americans have paid more for their prescription drugs than any developed nation. Today, the Biden-Harris Administration is delivering on its promise to lower out-of-pocket drug costs for seniors and save money for Americans. That’s because Medicare has the power to negotiate prescription drug prices for the first time in history thanks to the Inflation Reduction Act, which was signed into law by President Biden with Vice President Harris casting the tie-breaking vote. Because Medicare is now able to negotiate lower prescription drug prices for seniors and people with disabilities, American taxpayers are expected to save $6 billion on prescription drug costs, and people enrolled in Medicare are expected to save $1.5 billion in out-of-pocket costs in 2026 alone. President Biden and Vice President Harris took on Big Pharma and won, and now millions of seniors and others on Medicare will soon see their drug costs go down on some of the most common and expensive prescription drugs that treat heart disease, cancer, diabetes, blood clots, and more.
HHS Announces Negotiated Prices for Medicare Drugs
HHS has reached agreements with all participating manufacturers on new negotiated, lower drug prices for the first 10 drugs selected for the Medicare drug price negotiation program. After manufacturers have steadily increased the list prices of all 10 of these drugs since they went on the market, these new prices will cut the list price of these drugs between 38 and 79 percent.
The new prices will go into effect for people with Medicare Part D prescription drug coverage in 2026:
Drug Name
Commonly Treated Conditions
Number of Medicare Enrollees Who Used the Drug in 2023
Drug List Price in 2023 for 30-day Supply
Negotiated Price for 2026 for 30-day Supply
Savings (%)
Eliquis
Prevention and treatment of blood clots
3,928,000
$521
$231
$290 (-56%)
Jardiance
Diabetes; Heart failure; Chronic kidney disease
1,883,000
$573
$197
$376 (-66%)
Xarelto
Prevention and treatment of blood clots; Reduction of risk for patients with coronary or peripheral artery disease
These ten drugs are among those with highest total spending in Medicare Part D. If the negotiated prices had been in effect during 2023, Medicare would have saved an estimated $6 billion. When the negotiated prices go into effect in 2026, people enrolled in Medicare Part D are estimated to save $1.5 billion in out-of-pocket costs.
Millions of Part D enrollees that depend on these treatments to treat life-threatening conditions including diabetes, heart failure, and cancer are also expected to see lower out-of-pocket costs for these drugs. For example, a Medicare enrollee who takes Stelara for their arthritis and pays $3,459 on their drug today for a 30-day supply would pay only $1,174 in 2026. Many seniors and people with disabilities on Medicare who take these drugs will also benefit from the Inflation Reduction Act’s $2,000 cap on out-of-pocket spending, which will be fully in effect in 2025, saving 19 million beneficiaries an average of $400 per year, in addition to these savings from the negotiated drug prices.
More drugs will be selected each year as part of Medicare’s drug price negotiation program. Medicare will select up to 15 additional drugs covered under Part D for negotiation in 2025, up to an additional 15 Part B and D drugs in 2026, and up to 20 drugs every year after that.
Building on Progress Lowering Health Care Costs
Every day, millions of Americans are saving money on health care costs because of the Biden-Harris Administration’s actions.
People with Medicare are saving an average of $70 in out-of-pocket costs on vaccines like shingles and Tdap because President Biden’s Inflation Reduction Act made recommended vaccines free for beneficiaries, including the 10.3 million enrollees who received a free vaccine in 2023.
All 3.4 million Medicare Part D enrollees who filled an insulin prescription in 2023 had their insulin costs capped at $35 per month, saving some seniors hundreds of dollars for a month’s supply.
Some seniors and other Medicare beneficiaries taking drugs covered under Part B for which manufacturers have hiked prices faster than inflation are saving up to $4,593 in lower coinsurance this quarter thanks to the new Medicare inflation rebates.
Starting this year, Part D enrollees no longer pay 5% co-insurance when they reach the catastrophic phase of their benefit and have their out-of-pocket drug costs capped at about $3,500. In just the first quarter of 2024, over 260,000 people benefited from this cap.
Millions of American are saving an average of about $800 per year on health insurance premiums because of savings from the American Rescue Plan that the Inflation Reduction Act extended, helping drive the nation’s uninsured rate to historic lows under the Biden-Harris Administration.
Check out the Biden-Harris Administration’s Savings Explorer to see how some of the Administration’s policies are helping Americans save money on annual expenses – from health care to junk fees, grocery costs and more.
Continuing to Lower Prescription Drug Costs
People with Medicare will continue to see their prescription drug costs go down as more provisions of the Inflation Reduction Act go into effect next year. Nearly 19 million seniors and other Part D beneficiaries are projected to save $400 per year on prescription drugs when the out-of-pocket cap drops to $2,000 in 2025, and 1.9 million enrollees with the highest drug costs will save an average of $2,500 per year. And the lower prices negotiated for the high-spend drugs announced today will go into effect in 2026.
The President’s Budget for Fiscal Year 2025 builds on this success by significantly increasing the pace of negotiation, bringing more drugs into negotiation sooner after they launch, expanding the $2,000 out-of-pocket prescription drug cost cap beyond Medicare and into the commercial market, and other steps to build on the Inflation Reduction Act drug provisions. The Budget also includes proposals to curb inflation in prescription drug prices and extends the $35 cost-sharing cap for monthly prescriptions of insulin to the commercial market to lower drug costs for all Americans.
Statement from President Joe Biden on Lower Prescription Drug Prices
For years, millions of Americans were forced to choose between paying for medications or putting food on the table, while Big Pharma blocked Medicare from being able to negotiate prices on behalf of seniors and people with disabilities. But we fought back – and won.
Today, for the first time in history, my Administration is announcing that Medicare has reached agreements on new, lower prices with the manufacturers of all 10 drugs selected for the first round of drug price negotiation. When these lower prices go into effect, people on Medicare will save $1.5 billion in out-of-pocket costs for their prescription drugs and Medicare will save $6 billion in the first year alone. It’s a relief for the millions of seniors that take these drugs to treat everything from heart failure, blood clots, diabetes, arthritis, Crohn’s disease, and more – and it’s a relief for American taxpayers.
This historic milestone is only possible because of the Inflation Reduction Act, which passed with the leadership of Democrats in Congress, and with Vice President Harris casting the tie-breaking vote in the Senate – without a single Republican voting for it. We showed that major progress can be made for the American people when we work together to take on special interests, even as Big Pharma continues to go to court to try to block lower prices for consumers. But the Vice President and I are not backing down. We will continue the fight to make sure all Americans can pay less for prescription drugs and to give more breathing room for American families.
Statement from Vice President Kamala Harris on Lower Prescription Drug Prices
Every American should be able to access the health care they need no matter their income or wealth. That is why President Biden and I fought to lower the costs of health care with our Inflation Reduction Act, transformational legislation that I was proud to cast the tie-breaking vote on in the Senate. During the two years since President Biden signed this landmark bill into law, we have cut prescription drug costs, capped the cost of insulin at $35 a month, and lowered premiums for seniors and people with disabilities on Medicare – helping millions of families get the care they deserve.
Today, we are building on our work to lower costs and increase access to affordable prescription drugs by announcing that the Biden-Harris Administration has reached agreements with all participating manufacturers to lower prices for the first 10 drugs selected for the Medicare price negotiation program – from those that treat cancer to those that treat diabetes, heart disease, and blood clots. Thanks to our historic work to allow Medicare to negotiate lower drug prices, millions of Americans who rely on these drugs will save on their out-of-pocket costs. While people enrolled in Medicare are expected to save $1.5 billion in 2026 alone, American taxpayers will also save an estimated $6 billion.
Today’s announcement will be lifechanging for so many of our loved ones across the nation, and we are not stopping here. Additional prescription drugs will be selected each year as part of our Medicare drug price negotiation program. This includes up to 15 additional drugs covered under Medicare Part D for negotiation in 2025, up to an additional 15 Part B and Part D drugs in 2026, and up to 20 drugs every year after that.
From my time as Attorney General of California and a U.S. Senator, I have consistently worked to lower the costs of prescription drugs and fought to protect patients. As Attorney General, I held Big Pharma accountable for their deceptive and illegal practices. The record-breaking settlements that I won – for the people – amounted to more than $7 billion against pharmaceutical companies for their unsafe and unfair tactics. President Biden and I will never stop fighting for the health, wellbeing, and financial stability of the American people.
$3 billion in funding from President Biden’s Investing in America Agenda will accelerate progress toward the President’s commitment to replace every lead pipe in the country within a decade – that is if Biden and Democrats remain in power. This fact sheet is provided by the White House:
President Biden believes that every American should be able to turn on the tap and drink clean, safe water. But over 9 million homes, schools, day cares, and businesses receive their water through a lead pipe, putting people at risk of lead exposure. Lead is a neurotoxin that can irreversibly harm brain development in children, and it can also accumulate in the bones and teeth, damage the kidneys, and interfere with the production of red blood cells needed to carry oxygen. Due to decades of inequitable infrastructure development and underinvestment, lead poisoning disproportionately affects low-income communities and communities of color. There is no safe level of exposure to lead. That is why the President made a commitment to replace every lead pipe in the country within a decade and coordinated a whole of government effort to deploy resources and leverage every tool across federal, state and local government to address lead hazards through the Lead Pipe and Paint Action Plan.
As part of this unprecedented commitment, President Biden traveled to Wilmington, North Carolina, to announce $3 billion through his Investing in America agenda to replace toxic lead pipes. This investment, administered by the Environmental Protection Agency (EPA), is part of the historic $15 billion in dedicated funding for lead pipe replacement provided by the President’s Bipartisan Infrastructure Law. The announcement delivers funding to every state and U.S. territory to help address lead in drinking water while creating good-paying jobs, many of them union jobs. In addition, this program funding is part of the President’s Justice40 Initiative, which set a goal that 40% of the overall benefits of certain federal investments flow to disadvantaged communities, and is helping address the inequities of lead exposure.
Additionally, to further reduce lead exposure, the Department of Housing and Urban Development announced nearly $90 million in available funding to reduce residential health hazards in public housing, including lead-based paint hazards, carbon monoxide, mold, radon, fire safety, and asbestos, advancing the President’s Lead Pipe and Paint Action Plan.
The announcement from the EPA builds on more than $20 billion in water infrastructure investments that state and local governments have made through the President’s American Rescue Plan. North Carolina has invested close to $2 billion from the American Rescue Plan in more than 800 clean water, wastewater, and stormwater projects across the state and is using another $150 million to test for and remove lead hazards in every school and child care center across the state, a historic effort to remove lead from North Carolina schools.
In Wilmington, North Carolina, President Biden announced $76 million from his Bipartisan Infrastructure Law for lead pipe replacement across the state. The President also met with faculty and students from a Wilmington school that replaced a water fountain with high levels of lead with funding from his American Rescue Plan.
EPA estimates North Carolina has an estimated 300,000 lead pipes, and today the President will highlight his goal of replacing every lead pipe in the state. With today’s new investment of $76 million, the President has now delivered $250 million in Bipartisan Infrastructure Law funding to North Carolina for lead pipe replacement. This funding has already reached over 60 communities across the state to kick start lead pipe identification and replacement efforts.
One of these communities is Wilmington, North Carolina, which has already received over $4 million from the Bipartisan Infrastructure Law to identify and replace 325 lead pipes. Today, President Biden is announcing that the first Bipartisan Infrastructure Law-funded lead pipe replacement in Wilmington is now underway, kicking off this project for the city.
Progress Replacing Lead Pipes Across America
The Biden-Harris Administration is taking action to accelerate lead pipe replacement in communities across the country. The total lead pipe replacement funding announced by the Administration to date will replace up to 1.7 million lead pipes, protecting countless families and children from lead exposure.
To ensure that communities that bear most of the burden of lead exposure are not left behind in this opportunity, EPA and the Department of Labor are partnering directly with disadvantaged communities across the country to provide the support and technical assistance they need to secure funding for and execute lead pipe replacement initiatives. EPA has partnered with over 40 communities to date, and last November announced it would partner with 200 more communities through the EPA Get the Lead Out Initiative.
This work is also creating good-paying jobs, many of them union jobs, in replacing lead pipes – and accelerating the development of a skilled water workforce. Unions including the Laborers’ International Union of North America (LIUNA), the United Association of Plumbers and Pipefitters, and the International Union of Operating Engineers are already training workers in lead pipe replacement and putting them to work on neighborhood blocks across the country. The EPA estimates that 200,000 jobs have been created by the Administration’s investments in drinking water infrastructure alone.
In addition, last November, EPA issued a proposal to strengthen its Lead and Copper Rule that would require water systems to replace lead pipes within 10 years and drive progress nationwide toward reducing lead exposure.
The examples below highlight several communities where the Administration’s investments are making an impact:
In Milwaukee, Wisconsin, $41 million from the Bipartisan Infrastructure Law has helped put the city on track to replace all its lead pipes within 10 years instead of the initially estimated 60 years. The city is using a high proportion of union labor to replace lead pipes, and will be one of four new White House Workforce Hub cities that were announced by President Biden last week.
Following a lead-in-water crisis, Benton Harbor, Michigan, successfully replaced all its lead pipes within just two years, fueled by $18 million in funding from the President’s American Rescue Plan.
Pittsburgh, Pennsylvania, has received $42 million from the Bipartisan Infrastructure Law to replace lead pipes, and is on track to replace every lead pipe by 2026. Vice President Harris visited the city in February to highlight this progress in lead pipe replacement and announce new funding for clean water.
St. Paul, Minnesota, has received $16 million from the American Rescue Plan to replace lead pipes. This funding has enabled the city’s Lead-Free St. Paul program to target the replacement of all lead pipes by 2032 at no cost to residents.
Cincinnati, Ohio, passed an ordinance to develop a program to replace all lead pipes in line with the President’s goal, and authorized covering the cost of replacing private lead pipes that bring water to residents’ homes. A $20 million investment from the Bipartisan Infrastructure Law will support this work.
Tucson, Arizona, received $6.95 million to develop a Lead Service Line inventory for their nine public water systems. The city will use this inventory to develop a plan to replace lead service lines in the community and improve drinking water quality for residents – many of whom live in low-income and disadvantaged communities.
Denver, Colorado, has replaced almost 25,000 lead service lines since the program launched in 2020. Denver plans to replace another 5,000 this year and is on target to replace 100% by 2031, accelerating its lead pipe replacement due to Bipartisan Infrastructure Law funding.
Last week, at the White House Water Summit, the Great Lakes and St. Lawrence Cities Initiative launched its new Great Lakes Lead Pipes Partnershipwith three of its members – Chicago, Illinois, Detroit, Michigan, and Milwaukee, Wisconsin. This first-of-its kind, mayor-led effort to accelerate lead pipe replacement in cities with the heaviest lead burdens will provide a collaborative forum for metropolitan areas in the Great Lakes to share emerging best practices to encourage faster, more equitable replacement programs and overcome common challenges, including reducing replacement costs, improving community outreach, and spurring water workforce development.
Broader Administration Actions to Deliver Clean Water
The funding announced today is part of the over $50 billion provided by the Bipartisan Infrastructure Law to upgrade the nation’s water infrastructure – the largest investment in clean and safe water in American history. In addition, over $20 billion from the American Rescue Plan has been invested in water infrastructure, including lead pipe replacement, nationwide.
Beyond replacing lead pipes, these broader investments are helping to expand access to clean drinking water, improve wastewater and sanitation infrastructure, and remove per- and polyfluoroalkyl substances (PFAS) contamination in water. The Administration has launched over 1,400 of these projects to deliver clean water to date.
Delivering Clean Drinking Water. The Bipartisan Infrastructure Law invests nearly $31 billion in funding to secure clean drinking water through infrastructure projects such as upgrading aging water mains and improving water treatment plants.
Improving Wastewater and Sanitation Infrastructure. Over 2 million people in the U.S. live without basic running water or sanitation systems in their homes. The Bipartisan Infrastructure Law invests nearly $13 billion to improve wastewater, sanitation, and stormwater infrastructure.
Tackling PFAS Pollution in Water. Exposure to PFAS “forever chemicals” in drinking water is linked to severe health impacts including deadly cancers, liver and heart damage, and developmental impacts in children. The Bipartisan Infrastructure Law invests $10 billion to address toxic PFAS pollution in water. In addition, this month EPA announced the first-ever national drinking water standard for PFAS , which will protect 100 million people from PFAS exposure.
